UK markets closed

Sarepta Therapeutics, Inc. (SRPT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
118.87-0.47 (-0.39%)
As of 02:42PM EST. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 10.48B
Enterprise value 9.98B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)11.86
Price/book (mrq)24.32
Enterprise value/revenue 11.39
Enterprise value/EBITDA -16.46

Trading information

Stock price history

Beta (5Y monthly) 1.08
52-week change 339.60%
S&P500 52-week change 3-15.89%
52-week high 3127.32
52-week low 361.28
50-day moving average 3112.60
200-day moving average 392.37

Share statistics

Avg vol (3-month) 31.08M
Avg vol (10-day) 3977.83k
Shares outstanding 587.78M
Implied shares outstanding 6N/A
Float 883.76M
% held by insiders 14.38%
% held by institutions 189.05%
Shares short (14 Nov 2022) 47.35M
Short ratio (14 Nov 2022) 46.89
Short % of float (14 Nov 2022) 48.76%
Short % of shares outstanding (14 Nov 2022) 48.37%
Shares short (prior month 13 Oct 2022) 47.24M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:6
Last split date 311 Jul 2012

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022


Profit margin -81.76%
Operating margin (ttm)-61.03%

Management effectiveness

Return on assets (ttm)-11.49%
Return on equity (ttm)-159.10%

Income statement

Revenue (ttm)876.05M
Revenue per share (ttm)10.06
Quarterly revenue growth (yoy)21.60%
Gross profit (ttm)-165.84M
EBITDA -493.34M
Net income avi to common (ttm)-716.23M
Diluted EPS (ttm)-4.28
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)2.07B
Total cash per share (mrq)23.61
Total debt (mrq)1.6B
Total debt/equity (mrq)372.35
Current ratio (mrq)4.36
Book value per share (mrq)4.91

Cash flow statement

Operating cash flow (ttm)-262.28M
Levered free cash flow (ttm)110.41M